Literature DB >> 7976454

Prevalence of insomnia in elderly general practice attenders and the current treatment modalities.

F Hohagen1, C Käppler, E Schramm, K Rink, S Weyerer, D Riemann, M Berger.   

Abstract

This study aimed to assess the prevalence and treatment modalities of elderly practice attenders. A total of 330 patients aged over 65 years were investigated with a questionnaire in general practice. To assess insomnia, operationalized diagnostic criteria according to DSM-III-R were applied. Twenty-three percent of the elderly patients suffered from severe, 17% from moderate and 17% from mild insomnia. More than 80% of the patients reported suffering from insomnia for 1-5 years or longer, which indicates a chronic course. Elderly patients showed unrealistic expectations concerning duration of sleep and spend more time in bed than they realistically can expect to sleep. More than half of the elderly patients reported habitual daytime napping. Sleep-disturbed elderly patients did not differ significantly from good sleepers in their habit of taking daytime naps, but even when taking daytime naps, good sleepers slept significantly longer than the sleep-disturbed patients. A significant association was found between insomnia and mental disorders, i.e., depression and organic brain syndrome according to the diagnosis of the general physician. In about half of the cases the primary care physician was not aware that the elderly patient suffered from severe insomnia. More than half of the elderly severe insomniacs took prescribed hypnotics habitually, mainly benzodiazepines.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7976454     DOI: 10.1111/j.1600-0447.1994.tb01563.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  29 in total

1.  Primary Care: Is It the Setting to Address Sleep Disorders?

Authors:  William C. Dement; Nikolaus C. Netzer
Journal:  Sleep Breath       Date:  2000       Impact factor: 2.816

2.  A double-blind, placebo-controlled investigation of the residual psychomotor and cognitive effects of zolpidem-MR in healthy elderly volunteers.

Authors:  Ian Hindmarch; Eric Legangneux; Neil Stanley; Steve Emegbo; Jean Dawson
Journal:  Br J Clin Pharmacol       Date:  2006-11       Impact factor: 4.335

3.  The role of primary care physicans in sleep medicine.

Authors:  N C Netzer
Journal:  Sleep Breath       Date:  1997-03       Impact factor: 2.816

4.  [Insomnia and increased use of sleep medication among seniors: problems and alternative treatment].

Authors:  Lynda Bélanger; Annie Vallières; Charles M Morin
Journal:  Can Fam Physician       Date:  2006-08       Impact factor: 3.275

5.  Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International Classification of Sleep Disorders (ICSD).

Authors:  Maurice M Ohayon; Charles F Reynolds
Journal:  Sleep Med       Date:  2009-10       Impact factor: 3.492

6.  Sleep problems, psychiatric hospitalization, and emergency department use among psychiatric patients with Medicaid.

Authors:  Christopher N Kaufmann; Adam P Spira; Donald S Rae; Joyce C West; Ramin Mojtabai
Journal:  Psychiatr Serv       Date:  2011-09       Impact factor: 3.084

7.  Predictors of New Onset Sleep Medication and Treatment Utilization Among Older Adults in the United States.

Authors:  Amanda Leggett; Renee Pepin; Amanda Sonnega; Shervin Assari
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2016-01-11       Impact factor: 6.053

Review 8.  Optimal management of anxiety in older patients.

Authors:  K J Weiss
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

9.  Sleep in the Elderly: Burden, Diagnosis, and Treatment.

Authors:  W Vaughn McCall
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

10.  Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate.

Authors:  Thomas Roth; David Mayleben; Bruce C Corser; Nikhilesh N Singh
Journal:  Hum Psychopharmacol       Date:  2008-01       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.